Assessing Tumor Microenvironment of Metastasis Doorway-Mediated Vascular Permeability Associated with Cancer Cell Dissemination using Intravital Imaging and Fixed Tissue Analysis.
Journal
Journal of visualized experiments : JoVE
ISSN: 1940-087X
Titre abrégé: J Vis Exp
Pays: United States
ID NLM: 101313252
Informations de publication
Date de publication:
26 06 2019
26 06 2019
Historique:
entrez:
16
7
2019
pubmed:
16
7
2019
medline:
13
6
2020
Statut:
epublish
Résumé
The most common cause of cancer related mortality is metastasis, a process that requires dissemination of cancer cells from the primary tumor to secondary sites. Recently, we established that cancer cell dissemination in primary breast cancer and at metastatic sites in the lung occurs only at doorways called Tumor MicroEnvironment of Metastasis (TMEM). TMEM doorway number is prognostic for distant recurrence of metastatic disease in breast cancer patients. TMEM doorways are composed of a cancer cell which over-expresses the actin regulatory protein Mena in direct contact with a perivascular, proangiogenic macrophage which expresses high levels of TIE2 and VEGF, where both of these cells are tightly bound to a blood vessel endothelial cell. Cancer cells can intravasate through TMEM doorways due to transient vascular permeability orchestrated by the joint activity of the TMEM-associated macrophage and the TMEM-associated Mena-expressing cancer cell. In this manuscript, we describe two methods for assessment of TMEM-mediated transient vascular permeability: intravital imaging and fixed tissue immunofluorescence. Although both methods have their advantages and disadvantages, combining the two may provide the most complete analyses of TMEM-mediated vascular permeability as well as microenvironmental prerequisites for TMEM function. Since the metastatic process in breast cancer, and possibly other types of cancer, involves cancer cell dissemination via TMEM doorways, it is essential to employ well established methods for the analysis of the TMEM doorway activity. The two methods described here provide a comprehensive approach to the analysis of TMEM doorway activity, either in naïve or pharmacologically treated animals, which is of paramount importance for pre-clinical trials of agents that prevent cancer cell dissemination via TMEM.
Identifiants
pubmed: 31305525
doi: 10.3791/59633
pmc: PMC6784529
mid: NIHMS1053548
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Video-Audio Media
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : P01 CA100324
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA216248
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA200561
Pays : United States
Organisme : NIH HHS
ID : S10 OD019961
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA150344
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA013330
Pays : United States
Références
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Physiol Rev. 2011 Jul;91(3):1071-121
pubmed: 21742796
J Cell Sci. 2016 May 1;129(9):1751-8
pubmed: 27084578
Science. 2005 Jan 7;307(5706):58-62
pubmed: 15637262
J Natl Cancer Inst. 2014 Jun 03;106(8):
pubmed: 24895374
Cancer Discov. 2015 Sep;5(9):932-43
pubmed: 26269515
J Cell Sci. 1995 Jun;108 ( Pt 6):2369-79
pubmed: 7673356
Endocr Rev. 2015 Oct;36(5):564-91
pubmed: 26357922
Am J Hematol. 2010 Aug;85(8):593-8
pubmed: 20540157
Cancer Res. 2007 Sep 15;67(18):8429-32
pubmed: 17875679
Front Physiol. 2014 Mar 05;5:75
pubmed: 24634660
Cancer Cell. 2011 Apr 12;19(4):431-3
pubmed: 21481783
J Leukoc Biol. 2008 Feb;83(2):430-3
pubmed: 17971498
Mol Cancer Ther. 2017 Nov;16(11):2486-2501
pubmed: 28838996
Nat Methods. 2008 Dec;5(12):1019-21
pubmed: 18997781
Curr Opin Hematol. 2010 May;17(3):219-24
pubmed: 20308892
Clin Exp Metastasis. 2018 Oct;35(7):613-623
pubmed: 30136072
Cancer Cell. 2011 Apr 12;19(4):512-26
pubmed: 21481792
Mol Biol Cell. 1997 Apr;8(4):595-605
pubmed: 9247641
Proc Natl Acad Sci U S A. 2017 Aug 22;114(34):E7159-E7168
pubmed: 28784776
Biomark Med. 2015;9(2):81-4
pubmed: 25689896
Curr Protoc Cell Biol. 2013 Mar;Chapter 19:19.7.1-19.7.19
pubmed: 23456602
Nat Rev Drug Discov. 2011 Jun;10(6):417-27
pubmed: 21629292
Sci Transl Med. 2017 Jul 5;9(397):
pubmed: 28679654
Cancer Res. 2015 Sep 1;75(17):3479-91
pubmed: 26269531
Cell Rep. 2018 May 1;23(5):1239-1248
pubmed: 29719241
Nat Protoc. 2011 Sep 08;6(10):1500-20
pubmed: 21959234
Cancer Cell. 2004 Dec;6(6):553-63
pubmed: 15607960
Blood. 2003 Feb 1;101(3):1155-63
pubmed: 12393599
J Clin Oncol. 2013 Jun 10;31(17):2205-18
pubmed: 23669226
NPJ Breast Cancer. 2017 Nov 8;3:42
pubmed: 29138761
Clin Exp Metastasis. 2011 Aug;28(6):515-27
pubmed: 21484349
J Cell Sci. 2011 Jul 1;124(Pt 13):2120-31
pubmed: 21670198
J Vis Exp. 2016 Jun 12;(112):
pubmed: 27341448
Cancer Res. 2007 Mar 15;67(6):2649-56
pubmed: 17363585
Curr Opin Investig Drugs. 2005 Nov;6(11):1124-30
pubmed: 16312133
J Leukoc Biol. 2009 Nov;86(5):1065-73
pubmed: 19741157
Methods Mol Biol. 2016;1458:71-85
pubmed: 27581015
Science. 1983 Feb 25;219(4587):983-5
pubmed: 6823562
Clin Cancer Res. 2009 Apr 1;15(7):2433-41
pubmed: 19318480
Blood. 2007 Jun 15;109(12):5276-85
pubmed: 17327411
Exp Cell Res. 2010 May 1;316(8):1324-31
pubmed: 20211171
Nat Methods. 2018 Jan;15(1):73-80
pubmed: 29176592
Oncotarget. 2014 Apr 30;5(8):2208-20
pubmed: 24809734
J Cell Mol Med. 2007 Jul-Aug;11(4):621-43
pubmed: 17760829
Microcirculation. 1999 Jun;6(2):83-96
pubmed: 10466111
Am J Physiol Renal Physiol. 2009 May;296(5):F947-56
pubmed: 19129259
Intravital. 2016;5(2):
pubmed: 27790386
Sci Signal. 2014 Nov 25;7(353):ra112
pubmed: 25429076
Clin Exp Metastasis. 2018 Apr;35(4):269-284
pubmed: 29307118
Mol Aspects Med. 2011 Apr;32(2):123-45
pubmed: 21565215
Cancer Res. 1997 Feb 15;57(4):765-72
pubmed: 9044858
Cancer Discov. 2015 Sep;5(9):906-8
pubmed: 26334045
Methods. 2017 Sep 1;128:65-77
pubmed: 28911733
Handb Clin Neurol. 2016;133:39-59
pubmed: 27112670